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Summary
Background: ABL tyrosine kinases control actin re-
modeling in development and in response to environ-
mental stimuli. These changes affect cell adhesion, cell
migration, and cell-cell contact. Little is known, how-
ever, about upstream mechanisms regulating ABL pro-
tein activation.
Results: We report that the RAS effector RIN1 is an
activator of ABL tyrosine kinases. RIN1 expression in
fibroblasts promotes the formation of membrane
spikes; similar effects have been reported for ABL over-
expression. RIN1 binds to the ABL SH3 and SH2 do-
mains, and these interactions stimulate ABL2 catalytic
activity. This leads to increased phosphorylation of
CRK and CRKL, inhibiting these cytoskeletal regulators
by promoting intramolecular over intermolecular asso-
ciations. Activated RAS participates in a stable RAS-
RIN1-ABL2 complex and stimulates the tyrosine ki-
nase-activation function of RIN1. Deletion of the RAS
binding domain (RBD) strongly stimulated the ABL2 ac-
tivation function of RIN1, suggesting that RAS activa-
tion results from the relief of RIN1 autoinhibition. The
ABL binding domain of RIN1 (RIN1-ABD) increased the
activity of ABL2 immune complexes and purified RIN1-
ABD-stimulated ABL2 kinase activity toward CRK.
Mammary epithelial cells (MECs) from Rin1−/− mice
showed accelerated cell adhesion and increased motil-
ity in comparison to wild-type cells. Knockdown of
RIN1 in epithelial-cell lines blocked the induction of
CRKL phosphorylation, confirming that RIN1 normally
functions as an inhibitor of cell motility.
Conclusions: RIN1 is a directly binding ABL tyrosine
kinase activator in cells as well as in a defined-compo-
nent assay. In response to environmental changes, this
novel signal pathway mediates actin remodeling asso-
ciated with adhesion and migration of epithelial cells.
Introduction
The nonreceptor tyrosine kinases ABL1 (also known as
c-Abl) and ABL2 (also known as Arg) are similar in
structure and function [1]. Both proteins contain SH3,
SH2, and tyrosine kinase (TK) domains; in each case,
the domains exhibit >90% sequence identity. Both ABL
proteins also have leukemogenic potential that is un-
leashed by chromosome translocations [2–4]. The re-*Correspondence: colicelli@mednet.ucla.edusulting oncogenic fusion proteins always include the
SH3, SH2, and TK domains.
ABL proteins regulate cytoskeleton remodeling (re-
viewed in [5, 6]) during adhesion, motility, and axon guid-
ance. Consistent with this function, ABL proteins contain
actin binding sites [7–9], localize to dynamic actin
structures, and phosphorylate CRK and CRKL [10, 11],
DOK1 [12], and other proteins controlling cytoskeleton
dynamics [13]. Tyrosine phosphorylation of CRK/CRKL
promotes intramolecular refolding that excludes in-
teractions with CAS and blocks cell migration (reviewed
in [14]).
Inactive ABL kinases are stabilized by intramolecular
interactions including the following: (1) association be-
tween the SH3 domain and the SH2-TK linker region
[15], (2) interactions of a short amino-terminal “cap”
[16], and (3) contributions from an amino-terminal my-
ristoyl group [17] and phospholipids [18]. ABL kinase
activation is facilitated by autophosphorylation as well
as by SRC-family kinase-mediated phosphorylation
[19–21]. Intermolecular ABL binding partners that in-
hibit function include Abi1 [22], Abi2 [23], AAP1 [24],
PAG [25], and RB1 [26]. Although overexpression of
some genes can promote phosphorylation of ABL sub-
strates in vivo [27, 28], there are no reports of direct
ABL kinase activators.
RIN1 is a RAS-effector protein [29, 30] that binds to
ABL1 [29] and BCR-ABL1 [31]. The RIN1-ABL1 interac-
tion appears to involve the SH3 and SH2 domains of
ABL1 [31, 32], but the mechanism of binding and the
consequences of this association were previously not
known. The expression of RIN1 protein is restricted [33]
but includes some epithelial cells.
We report that RIN1 is a binding partner for ABL2 as
well as for ABL1, that RIN1 phosphorylation by ABL is
required for stable binding, that RIN1 functions to stim-
ulate ABL2 activity in a RAS-responsive manner, and
that the ABL binding domain of RIN1 can directly en-
hance ABL2-mediated phosphorylation of CRK. We
also show that RIN1 promotes the cytoskeletal-remod-
eling properties of ABL proteins and serves in part to
regulate epithelial-cell functions including adhesion
and migration.
Results
RIN1 Functions through ABL Kinases to Induce
Actin Remodeling
We introduced RIN1 into fibroblast cells, which nor-
mally have undetectable levels of this protein. When
plated on fibronectin, RIN1-expressing cells showed a
striking change in morphology (Figure 1A). We noted
the appearance of microspike structures and a de-
crease in actin stress fibers, similar to changes seen
after overexpression of ABL1 [12, 34]. RIN1-expressing
cells also had a rounded-up morphology (Figure 1B;
cell height: 8.3 ± 0.6 m [vector], 14.8 ± 1.2 m [RIN1]).
Microspike formation was also observed when we ex-
pressed the ABL binding domain alone (RIN1-ABD, Fig-
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816Figure 1. RIN1 Expression Promotes ABL-
Dependent Actin Remodeling in Fibroblasts
(A) NIH3T3 cells, infected with a RIN1 or vec-
tor retrovirus and stained with phalloidin
(green) and anti-RIN1 (red). RIN1 effects
were blocked by STI571.
(B) At top, XZy confocal analysis, phalloidin
(green) stain; at bottom, XYz confocal analy-
sis and phalloidin (green) and anti-RIN1 (red)
staining of the same cells as on top.
(C) NIH3T3 cells expressing the ABL binding
domain alone (RIN1-ABD) or the triple Y/F
mutation (RIN1-ABDTM) from a green-fluo-
rescent-protein (GFP) vector. The phalloidin
stain was red in this experiment.
(D) MEFs, infected with a RIN1 or vector ret-
rovirus and stained with phalloidin (green).
RIN1 induced membrane spikes in wild-type
but not in Abl1−/−Abl2−/− MEFs.ure 1C). These results are consistent with RIN1 activa-
ation of an ABL-mediated pathway. Treatment with
STI571, a potent inhibitor of both ABL1 and ABL2, ef- i
Afectively blocked cell remodeling (Figure 1A) but had no
effect on the morphology of NIH3T3 cells not express- A
Aing RIN1 (data not shown). To confirm that RIN1-
induced remodeling was ABL dependent, we compared l
cthe effects of RIN1 expression in mouse embryo fibro-
blast (MEF) cells from wild-type and Abl1−/−Abl2−/− ani- T
bmals [35]. The absence of ABL1 and ABL2 blocked the
ability of RIN1 to induce cell shape changes (Figure 1D), c
calthough these cells remain responsive to ABL (Figure
S1 in the Supplemental Data available with this article m
conline).
A
tRIN1 Is a Binding Partner of ABL Tyrosine Kinases
When ABL2 was immunoprecipitated from cell extracts, A
ewe observed copurification of RIN1 (Figure 2A, left), in-
dicating a stable protein complex. This was confirmed d
iby reciprocal analysis (RIN1 immunoprecipitation fol-
lowed by ABL2 immunoblot; Figure 2A, right). We also R
fdetected an interaction between ectopically expressed
RIN1 and ABL1 (Figure 2B, left) as well as between en- t
dogenous epithelial-cell RIN1 and ABL1 (Figure 2B, right).
The RIN1-ABL1 coimmunoprecipitation appeared weaker p
fthan that of RIN1-ABL2, perhaps reflecting ABL1 distri-
bution in both the cytoplasm and the nucleus. (Because RIN1 is phosphorylated by ABL1 in vitro [29]
nd by BCR-ABL1 in vivo [31], we tested whether RIN1
s subject to tyrosine phosphorylation by endogenous
BL proteins and whether this was required for RIN1-
BL binding. RIN1 ectopically expressed in wild-type,
bl1−/−, or Abl2−/− MEF cells was tyrosine phosphory-
ated (Figure 3A), but RIN1 expressed in Abl1−/−Abl2−/−
ells had no detectable tyrosine phosphorylation.
hese findings suggested that RIN1 is phosphorylated
y both ABL1 and ABL2. Because RIN1 tyrosine 36
onforms to both the general tyrosine-phosphorylation
onsensus (R/K-X2-3-D/E-X2-3-Y) and the ABL substrate
otif (YxxP), we developed a RIN1pY36 phosphospe-
ific antibody to monitor RIN1 phosphorylation by
BL1 and ABL2. Anti-RIN1pY36 was highly specific for
yrosine-phosphorylated RIN1 in cells coexpressing
BL2 (Figure 3B). In addition, the antibody recognized
ndogenous RIN1pY36 in KCL22 cells, a leukemia-
erived cell line expressing BCR-ABL1 (Figure 3B), and
n forebrain tissue, which has high levels of ABL2 and
IN1 [33, 35]. The identified RIN1pY36 band was absent
rom Rin1−/− tissue and showed reduced intensity in ex-
racts from Abl2−/− forebrains (Figure 3C).
We next tested whether phosphorylation by ABL
roteins is required for RIN1 binding. When cotrans-
ected with RIN1, a catalytically inactive form of ABL2
ABL2K319R) gave only low levels of RIN1pY36 and weak
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817Figure 2. RIN1 Is Associated with ABL Pro-
teins
(A) Anti-Flag (ABL2)-immunoprecipitated
material was immunobloted with anti-RIN1
(left), and anti-RIN1-immunoprecipitated ma-
terial was immunobloted with anti-Flag
(right). These immunoblots used extracts from
transfected 293T cells.
(B) RIN1 binding to ABL1 was assessed with
anti-RIN1 or anti-ABL1 immunoprecipitation
from extracts of transfected 293 cells. The
right side shows immunoprecipitation of en-
dogenous RIN1 with endogenous ABL1 from
MCF10A cells when anti-ABL1 but not anti-
Flag (control) was used.
(C) RIN1 tyrosine phosphorylation is required
for ABL2 binding. RIN1 was efficiently coim-
munoprecipitated with wild-type ABL2-Flag
or a phosphorylation-site mutant (ABL2Y439F)
but not with a kinase inactive mutant
(ABL2K319R).
(D) RIN1 tyrosine phosphorylation is required
for ABL2 binding. RIN1-ABD and an SH2 mu-
tant (RIN1-ABDR94N), but not a triple-tyrosine
mutant (RIN1-ABDTM), coimmunoprecipi-
tated with ABL2-Flag. Whole-cell-extract im-
munoblots were used to confirm expression
of transfected constructs.RIN1. Subsequent connection of this phosphotyrosine lation-site mutant of ABL2 (Figure 4A), providing evi-
Figure 3. RIN1 Is Phosphorylated by ABL
Kinases
(A) RIN1 was introduced into MEF cells and
analyzed by anti-RIN1 immunoprecipitation
followed by anti (α)-pTyr immunoblot (upper
panel) or anti (α)-RIN1 immunoblot (lower
panel). For Abl1−/−Abl2−/− cells, matched
day-9 MEFs were used because of early le-
thality [34]. Control cells were not infected
with RIN1.
(B) Detection of ectopic phospho-RIN1 in transfected 293T cells (left) and endogenous phospho-RIN1 in BCR-ABL1-positive KCL22 cells
(right) with anti-RIN1pY36.
(C) Detection of endogenous RIN1pY36 in forebrain tissue extracts prepared from adult mice of the indicated genotype. Rin1 was immunopre-
cipitated with anti-Rin1 and analyzed by immunoblot with anti-RIN1pY36 or anti-Rin1. Brain extracts were normalized with an anti-β tubulin
probe prior to immunoprecipitations.ABL2-RIN1 binding (Figure 2C). The detectable RIN1pY36
likely reflects the action of endogenous ABL1 and
ABL2. Mutation of an activation-loop phosphorylation
site (Y439) required for optimum kinase activity [21] had
no effect on RIN1 phosphorylation or binding (Fig-
ure 2C).
We confirmed the requirement for RIN1 tyrosine
phosphorylation in ABL2 binding through the use of a
mutant form of the ABL binding domain (ABD). RIN1-
ABDTM has three tyrosines mutated to phenylalanines
(in the absence of Y36, two other tyrosines within the
ABD [Y121 and Y148] are phosphorylated by BCR-ABL1
[31]). RIN1-ABDTM was impaired for binding to ABL2
(Figure 2D) and failed to induce membrane spikes in
NIH3T3 cells (Figure 1C). A mutation (R94N) in the RIN1
SH2 domain, which mediates receptor tyrosine kinase
interactions [36], had no effect on ABL binding.
These results are consistent with a protein-interac-
tion model that is initiated by a weak association be-
tween the RIN1 proline-rich motif and the ABL SH3 do-
main and is followed by tyrosine phosphorylation ofto the ABL SH2 domain produces a stable two-site as-
sociation.
Stimulation of ABL2 Tyrosine Kinase Activity
by RIN1
To determine whether RIN1 could influence the cata-
lytic activity of ABL proteins, we examined cellular tyro-
sine-phosphorylation levels. Autophosphorylated ABL2
protein was easily detectable, and this was noticeably
elevated when RIN1 was coexpressed in cells (Figure
4A). Phosphorylated RIN1 was also clearly evident
(293T cells have extremely low levels of endogenous
RIN1 [data not shown]). Several additional, unidentified
bands also appeared in extracts coexpressing ABL2
and RIN1, indicating a broader induction of tyrosine
phosphorylation. The new phosphotyrosine bands most
likely reflect ABL2 stimulation because these bands
were absent in extracts from cells transfected with
ABL2K319R, the kinase dead mutant (Figure 4A). We also
found that RIN1 expression increased cellular tyrosine
phosphorylation by ABL2Y439F, a regulatory phosphory-
Current Biology
818Figure 4. RIN1 Promotes ABL2 Kinase Activity
(A and B) Transfected 293T cell lysates were analyzed by immunoblot with anti-phosphotyrosine. ABL2 and RIN1 expression were confirmed
by separate immunoblots (bottom panels). Note that in panel (B), gradient PAGE led to altered protein mobility.
(C) Analysis of cellular phosphotyrosine after treatment of cells with STI571 (10 M).
(D) Endogenous CRKL was immunoprecipitated from lysates of cells transfected with the indicated constructs and was immunoblotted
with anti-phosphotyrosine. * indicates an HTM tag, which reduces RIN-ABD migration in comparison to panels (B) and (C). Relative CRKL
phosphorylation levels are indicated at the bottom of each lane. Immunoblots confirming expression and normalized CRKL levels are
shown below.
(E) Endogenous CRKL was immunoprecipitated from forebrain extracts of wild-type (wt) and Rin1−/− mice and analyzed by anti-phosphotyro-
sine immunoblot. Below is a CRKL immunoblot for normalization.
(F) Analysis of ABL1 and ABL2 in wild-type and Rin1−/− brain extracts (several background bands are seen with this ABL1 antibody). Expres-
sion levels were normalized with a β-tubulin probe.dence that RIN1 alters the catalytic properties of ABL2, A
uat least in part, independently of this phosphoacti-
vation. w
ABecause all of the elements required for ABL binding
reside in the ABD region of RIN1 (residues 1–295), we e
tested whether this domain alone could stimulate tyro-
sine kinase activity. Indeed, we detected strong stimu- t
blation of ABL2-mediated cellular phosphotyrosine by
the ABD fragment of RIN1 (Figure 4B). However, RIN1- [
pABDTM, which cannot bind to BCR-ABL1 [32] or ABL2
(this work), did not stimulate tyrosine kinase activity e
o(Figure 4B). To confirm that immunoblot signals were
due to ABL tyrosine kinase activity, the experiment was A
prepeated with cells treated with STI571. Most of the
antiphosphotyrosine signal was eliminated (Figure 4C), a
although, under these conditions, some phosphory-
lated RIN1-ABD was still detectable. Taken together, D
Wthese results indicated that RIN1 promotes activation
of ABL2 through a direct interaction. s
pWe next examined the phosphorylation of CRKL, an
ABL kinase substrate. Consistent with phosphotyrosine a
Aanalyses of total cells, we observed a marked increase
in tyrosine phosphorylation of endogenous CRKL when bBL2 was expressed with RIN1 or with RIN1-ABD (Fig-
re 4D). An increase in tyrosine-phosphorylated CRKL
as also noted in the sample that received only RIN1-
BD (compare lanes 1 and 6), reflecting stimulation of
ndogenous ABL proteins.
To determine whether RIN1 is a physiological regula-
or of CRKL phosphorylation, we analyzed mouse fore-
rain tissue, where RIN1 is expressed at highest levels
33]. We detected a band corresponding to tyrosine-
hosphorylated CRKL, the intensity of which was mark-
dly reduced in a Rin1−/− tissue sample (Figure 4E). The
bserved change was not due to reduced ABL1 or
BL2 expression (Figure 4F). These results further sup-
ort a role for RIN1 in promoting the ABL kinase-medi-
ted phosphorylation of CRKL.
irect Activation of ABL Tyrosine Kinase Activity
e next performed in vitro kinase assays with a con-
ensus ABL1/ABL2-substrate peptide [37] and ABL2
rotein immunoprecipitated from cell lysates. Kinase
ctivity was detected in material from ABL2 and
BL2Y439F cell lysates, but ABL2K319R yielded only
ackground activity (Figure 5A). Coexpression of RIN1-
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(A) Samples immunoprecipitated with anti-Flag from cells trans-
fected with ABL2-Flag (wt or mutant) and RIN1 constructs were
used in kinase assays with ABL-substrate peptide. ABL2 levels in
each assay were normalized by immunoblot. Error bars represent
standard deviations calculated from results obtained with tripli-
cate samples.
(B) Kinase assays with purified His6-ABL2 (1.5 nM), GST-CRK or
GST-CRKY222F (chicken) (17 nM), and RIN1-ABD-His6 (5 nM or 10
nM). The RIN1-ABD effect is time dependent and concentration de-
pendent.
(C) Kinase assays with purified His6-ABL2 (1 nM), His6-CRKII (hu-
man) (1 M), and RIN1-ABD-His6 (± STI571 [10 M]). The normal-
ized change in phospho-CRK is indicated below the immunoblot
(Fold).ABD enhanced the activity of ABL2 by 3.3-fold, sug-
gesting that RIN1, which coimmunoprecipitates with
ABL proteins, stimulates ABL2 activity. The ABL2Y439F
mutant showed compromised basal activity but was
stimulated (4.2-fold) by coexpression with RIN1-ABD
(Figure 5A), consistent with the effects seen on total
cellular tyrosine phosphorylation (Figure 4A) and indi-
cating that RIN1-mediated stimulation is independent
of ABL2Y439 phosphorylation.
We next employed a purified-protein system to test
whether RIN1 could directly stimulate ABL2. The kinase
activity of ABL2 showed only a minor increase when
RIN1-ABD was included in the peptide phosphorylation
assay (data not shown). Using 10 nM of ABL2 and 10
M of peptide, we observed only 1.4-fold (100 nM ABD)
and 1.8-fold (1 M ABD) increases in activity in compar-
ison to assays with no ABD (n = 9 for each condition),
suggesting that enhancement of ABL-substrate-pep-tide phosphorylation may require RIN1-induced changes
in a cellular context.
To more closely approximate a natural ABL substrate,
we used GST-CRK (chicken CRKII) (Figure 5B). Phos-
phorylation was specific for the ABL target site (Y222,
equivalent to Y221 of mammalian CRKII) because GST-
CRKY222F was not phosphorylated under the same con-
ditions. RIN1-ABD had a stimulatory effect on CRK
phosphorylation (up to 4.9-fold), and this was both con-
centration- and time-dependent. Further assays were
performed with human CRKII, with similar results (Fig-
ure 5C). The inhibitory effect of STI571 confirmed that
the assay was detecting primarily ABL kinase activity
(Figure 5C). These results suggest that ABL stimulation
is an intrinsic property of RIN1, at least with regard to
the CRK substrate. Cellular factors may participate in
vivo to further modulate these effects.
RAS-RIN1-ABL2: A Signal-Transduction Pathway
We examined whether RIN1, a known RAS effector, can
function as a physical conduit for signal transduction
from RAS to ABL proteins. Expression of HRASG12V (ac-
tivated RAS), RIN1, and ABL2 resulted in the formation
of a complex including all three proteins, as detected
by immunoprecipitation of either ABL2 or HRAS (Figure
6A). In each case, the association of HRAS with ABL2
was dependent on the presence of RIN1. The formation
of this stable complex is consistent with a pathway
connecting RAS proteins with the cytoplasmic func-
tions of ABL-family tyrosine kinases through RIN1.
The RIN1-ABD fragment appeared to be more potent
than full-length RIN1 as a stimulator of ABL2 kinase
activity (Figure 4D, Figure 6B), suggesting that the RAS
binding domain of RIN1 might be a negative regulator
of the ABL activation function. We therefore tested
whether activated RAS could enhance the ABL2 stimu-
lation capacity of RIN1. Indeed, the coordinated ex-
pression of RASG12V with RIN1 significantly enhanced
the activation of ABL2 and cellular phosphotyrosine
levels when compared with the results for RIN1 + ABL2
or RASG12V + ABL2 (Figure 6B). This observation is con-
sistent with a signaling pathway from activated RAS
through RIN1, leading to stimulation of ABL kinases.
The specificity of enhanced phosphorylation was ex-
amined by direct evaluation of phospho-CRKL. The
ABL2-mediated phosphorylation of endogenous CRKL
was stimulated 7.5-fold by RIN1, and this was in-
creased to 11-fold by coexpression of RASG12V (Figure
6C). The highest levels of CRKL phosphorylation (17-
fold) were seen when the RIN1-ABD construct was
used, consistent with a derepression role for RAS in the
activation of RIN1 (Figure 6D).
RIN1 Regulates Adhesion and Migration
Cell adhesion and spreading require regulated activity
of ABL tyrosine kinases [6, 12, 34]. To test whether RIN1
is involved in cell attachment, we examined the proper-
ties of mammary epithelial cells (MECs), which normally
express RIN1. MECs from Rin1−/− mice showed higher
levels of attachment to fibronectin than did MECs from
wild-type mice after incubation for 15 min (5-fold) or 30
min (2-fold) (Figure 7A, left). Moreover, a striking mor-
phology difference between Rin1−/− and wild-type
Current Biology
820Figure 6. HRAS, RIN1, and ABL2 Form a Complex
(A) Transfected cell lysates were subjected to immunoprecipitation with anti-Flag (ABL2) or anti-RAS, and immunoblot for ABL2, RIN1, and
RAS followed. Separate immunoblots (lower panels) confirmed expression.
(B) Lysates of transfected 293T cells were analyzed by immunoblot with anti-phosphotyrosine (upper panel) or antibodies to ectopically
expressed proteins. Expected positions of phosphorylated ABL2-Flag, RIN1, and RIN1-ABD are indicated.
(C) Endogenous CRKL was immunoprecipitated and then immunoblotted with anti-phosphotyrosine to detect phospho-CRKL (the stimulation
of CRKL phosphorylation, normalized to ABL2-only cells, is indicated below the immunoblot [Fold]). Anti-CRKL immunoblot was the immuno-
precipitation control (intense band indicates position of IgG). Lower panels show immunoblots for ectopic proteins.
(D) Model for RIN1 activation of ABL proteins. RIN1 binds to ABL proteins through the following: (1) SH3 domain (ABL) binding to proline-rich
domain (RIN1), (2) tyrosine phosphorylation of RIN1, and (3) SH2 domain (ABL) binding to pY (RIN1). RIN1 promotes tyrosine phosphorylation
of ABL substrates. Phospho-CRK and -CRKL refold to accommodate an intramolecular SH2-pTyr pairing while disengaging from remodeling
and promigration complexes that include CAS and other proteins (X). RAS appears to stimulate RIN1 through derepression. Some RIN1
effects may result from direct competition with other RAS effectors.MECs was observed after attachment to fibronectin. p
pRin1−/− mutant cells showed extensive, striated, periph-
eral-actin networks (about 50% of total cell diameter), v
cwhereas wild-type cells showed much thinner cortical-
actin staining (Figure 7B). Treatment of wild-type MECs n
kwith the ABL inhibitor STI571 enhanced attachment
(Figure 7A, right) and resulted in peripheral-actin fiber c
Cnetwork extensions (Figure 7B), consistent with a
model in which ABL proteins normally inhibit or delay A
aepithelial-cell attachment and spreading.
The extended peripheral-actin fiber networks seen in a
aRin1−/− cells may represent extensions used in cell mi-
gration. Migration is essential in development and wound
healing but contributes to the malignancy of epithelial- D
cell-derived tumors. Indeed, we observed that Rin1−/−
MECs migrated toward hepatocyte growth factor (HGF) A
Rat a higher rate than did wild-type MECs (Figure 7C).
To confirm the role of RIN1 in regulating cell migration, o
twe employed small interfering RNA (siRNA) to knock
down RIN1 expression 10-fold in the human mammary A
cepithelial-cell line MCF10A (Figure 7D). A negative-con-
trol siRNA at the same concentration had no effect S
t(data not shown). RIN1 siRNA reduced CRKL phos-
phorylation levels (Figure 7D) and blocked CRKL phos- 1horylation induced by fibronectin (integrin activation)
lus HGF (MET-receptor activation) (Figure 7E). Con-
ersely, CRKL tyrosine phosphorylation in MCF10A
ells was increased by expression of RIN1-ABD (2-fold,
ormalized) but not of RIN1-ABDTM (Figure 7F). RIN1
nockdown also enhanced cell migration (Figure 7G),
onsistent with a positive role for an unphosphorylated
RKL complex in cell motility [38]. As expected, the
BL inhibitor STI571 reduced CRKL phosphorylation
nd promoted migration of MCF10A cells on fibronectin
nd HGF (Figure 7H), as it does in thyroid cells [39] and
s the deletion of ABL genes does in fibroblasts [11].
iscussion
Novel ABL Activation Pathway
IN1 binding stimulates ABL2 activity, providing the
nly example of an ABL kinase activator that can func-
ion in a purified-protein system. RIN1 may activate
BL2 by inducing a conformational change that in-
reases catalytic activity; binding to both the SH3 and
H2 domains of ABL would be predicted to relieve au-
oinhibitory aspects of the inactive ABL structure [6,
7]. This is consistent with the ability of RIN1 to rescue
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821Figure 7. RIN1 Regulates ABL-Mediated Cytoskeletal Remodeling of Mammary Epithelial Cells
(A) Attachment of wild-type and Rin1−/− (KO) MECs to fibronectin-coated surfaces was measured at 15 min and 30 min after plating (left). In
a separate experiment, a 30 min attachment was carried out in the presence or absence of STI571 (right).
(B) Wild-type and Rin1−/− MECs were attached to fibronectin-coated coverslips for 30 min, fixed and stained with anti-keritin (epithelial-cell
marker, green) and phalloidin (red). Representative cells are presented.
(C) Migration of wild-type and Rin1−/− MECs through Boyden chambers toward HGF over 4 hr. Immunoblot (top) confirms Rin1 expression
status.
(D) siRNA-mediated RIN1 knock down in MCF10A cells. The following are shown: at top, immunoblot of immunoprecipitated RIN1 from mock
or RIN1-specific siRNA-treated cells (10-fold reduction); at middle, the same cells plated on fibronectin plus HGF for 30 min and an anti-pTyr
immunoblot of immunoprecipitated CRKL (5.4-fold reduction of phospho-CRKL); at bottom, total CRKL levels (no change). Parallel treatment
with control siRNA had no effect (data not shown).
(E) MCF10A cells were kept in suspension (lanes 1 and 2) or plated on fibronectin with HGF (FN/HGF, lanes 3 and 4). RIN1 knock down (lanes
2 and 4) blocked the induction of CRKL phosphorylation resulting from treatment with fibronectin and HGF.
(F) RIN1-ABD, RIN1-ABDTM, or vector was expressed in MCF10A cells, and levels of phospho-CRKL were analyzed by immunoprecipitation
and immunoblot.
(G) Migration of wild-type or RIN1 knockdown (siRNA) MCF10A cells through Boyden chamber over 16 hr.
(H) Migration of MCF10A cells, ± 10 M STI571, through Boyden chamber over 4 hr.the kinase activity of a regulatory phosphorylation-site
mutant of ABL2 in vivo (this work) and the transform-
ing activity of BCR-ABL1 with a corresponding muta-
tion [31], and it suggests that RIN1 acts, at least in
part, independently of SRC kinase-mediated ABL1Y412/
ABL2Y439 phosphorylation and activation [21].
In a purified-protein system, RIN1-ABD enhanced
ABL2 kinase activity for CRK but not for a peptide sub-
strate, suggesting that RIN1 may work in part by pro-
viding a surface that facilitates docking of ABL sub-
strates such as CRK and CRKL. We observed the
highest level of ABL kinase stimulation in vivo, where
RIN1 might recruit binding partners or modifying en-
zymes that enhance ABL function. This is clearly not
the sole mechanism for ABL activation, however, be-
cause Rin1−/− mice develop normally [33] whereas an
Abl1−/−Abl2−/− double mutation is lethal [35]. RIN1 sig-
naling may instead be restricted to a limited number of
cell types and a select set of cell stimulations.
Deletion of the RAS binding domain (RBD) of RIN1resulted in a heightened ability to stimulate ABL2. This
demonstrates that the structural determinants for ABL
activation are within the ABD region (amino acids
1–295) and suggests that the RBD behaves as a nega-
tive regulator that is derepressed by RAS binding (Fig-
ure 6D). An analogous deletion of the RBD of RAF1 re-
sults in constitutively activated RAF (reviewed in [40]).
Regulation of Cytoskeletal Remodeling
and Epithelial-Cell Function by RIN1
ABL proteins have a particularly important role in epi-
thelial biology. Disruption of both mouse Abl genes
causes severely malformed neuroepithelial structures
with abnormal actin networks [35]. Mutations in fly Abl
lead to excess cortical actin and defects in epithelial
architecture [41, 42]. In mammalian epithelial cells, the
ABL substrate CRK regulates adherens junctions and
epithelial-mesenchymal transitions [43]. Rin1−/− MECs
showed rapid cell-substratum adhesion, enhanced pe-
ripheral-actin fiber networks, and increased cell motil-
Current Biology
822Kity. These results suggest that, as a positive regulator
Kof ABL-mediated cell remodeling, RIN1 normally favors
Ocell-cell interactions and may function to inhibit epithe-
s
lial-to-mesenchymal transitions such as those associ- p
ated with tumor progression and metastasis. Indeed, W
RIN1 appears to be downregulated in human breast tu-
mor cells [44].
R
The remodeling that accompanies epithelial-cell ad- R
hesion and motility likely involves the adaptor proteins A
PCRK and CRKL, known ABL substrates [11] that coordi-
nate the functions of CAS and other proteins. Tyrosine
Rphosphorylation of CRK/CRKL leads to an intramolecu-
lar SH2-pY interaction that disrupts intermolecular in-
teractions with CAS and inhibits cell motility [45] (Figure
6D). Conversely, CRKY221F increases both CAS binding
and cell motility [38]. We observed reductions in CRKL
phosphorylation in Rin1−/− tissues and cells and in
siRNA-treated cells, both of which correlated with in-
creased cell motility. We also found a stimulation of en-
dogenous CRKL phosphorylation by RIN1 in cells ex-
pressing ABL2 and enhanced CRK phosphorylation by
RIN1-stimulated ABL2 in vitro. These data suggest that
RIN1 functions, at least in part, through regulation of
ABL-mediated CRK/CRKL phosphorylation. Attenua-
tion mechanisms for RAS-RIN1-ABL signaling may
include dephosphorylation of RIN1 or ABL [46], 14-3-3-
mediated redistribution of RIN1 [30], or ubiquitination-
mediated protein degradation of ABL [47].
RIN1 expression is highest in mature forebrain neu-
rons, where ABL2 is also highly expressed. Rin1−/− mice
display a striking enhancement of long-term potentia-
tion (LTP) and learning [33], functions that are in part
dependent on actin remodeling [48], suggesting that
RIN1 negatively regulates ABL-mediated neuronal plas-
ticity. In hematopoietic cells, BCR-ABL1 is a potent
oncoprotein that works in part through cytoskeletal re-
modeling [2, 7, 49] correlated with CRKL phosphoryla-
tion. The ability of RIN1 to promote leukemogenesis by
BCR-ABL1 [31] and the correlation of RIN1 expression
with leukemogenesis [50] are consistent with an ABL
activation function. It should be noted that RIN1 also
1encodes a RAB5-exchange-factor domain that acti-
vates RAB-mediated endocytosis [36, 51], another func-
tion that requires cytoskeletal remodeling. The RAB5-
GEF domain of RIN1 is not present, however, in the
RIN1-ABD fragment that can activate ABL. 1
The properties of RIN1 establish it as a novel RAS
effector regulating ABL tyrosine kinase activity and cy-
1toskeletal remodeling. These findings should provide a
greater understanding of stimulus-induced actin reor-
ganization during epithelial-cell transitions, as well as
insights into the tumorigenic and neurobiological prop- 1
erties of RAS and ABL proteins.
1
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